Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Larysa, Wang, Yucai, Siegel, David S., Wang, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929758/
https://www.ncbi.nlm.nih.gov/pubmed/27363983
http://dx.doi.org/10.1186/s13045-016-0283-0
_version_ 1782440651424530432
author Sanchez, Larysa
Wang, Yucai
Siegel, David S.
Wang, Michael L.
author_facet Sanchez, Larysa
Wang, Yucai
Siegel, David S.
Wang, Michael L.
author_sort Sanchez, Larysa
collection PubMed
description Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.
format Online
Article
Text
id pubmed-4929758
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49297582016-07-02 Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma Sanchez, Larysa Wang, Yucai Siegel, David S. Wang, Michael L. J Hematol Oncol Review Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM. BioMed Central 2016-06-30 /pmc/articles/PMC4929758/ /pubmed/27363983 http://dx.doi.org/10.1186/s13045-016-0283-0 Text en © Sanchez et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Sanchez, Larysa
Wang, Yucai
Siegel, David S.
Wang, Michael L.
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
title Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
title_full Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
title_fullStr Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
title_full_unstemmed Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
title_short Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
title_sort daratumumab: a first-in-class cd38 monoclonal antibody for the treatment of multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929758/
https://www.ncbi.nlm.nih.gov/pubmed/27363983
http://dx.doi.org/10.1186/s13045-016-0283-0
work_keys_str_mv AT sanchezlarysa daratumumabafirstinclasscd38monoclonalantibodyforthetreatmentofmultiplemyeloma
AT wangyucai daratumumabafirstinclasscd38monoclonalantibodyforthetreatmentofmultiplemyeloma
AT siegeldavids daratumumabafirstinclasscd38monoclonalantibodyforthetreatmentofmultiplemyeloma
AT wangmichaell daratumumabafirstinclasscd38monoclonalantibodyforthetreatmentofmultiplemyeloma

Ejemplares similares